Why carry out this study?

There is currently no direct head-to-head evidence of the long-term efficacy of bimekizumab compared to other interleukin (IL)-17A inhibitors in psoriatic arthritis (PsA)

This study uses matching-adjusted indirect comparisons (MAICs) to compare the efficacy of bimekizumab 160 mg every 4 weeks (Q4W) and secukinumab 150 mg and 300 mg Q4W at 52 weeks for the treatment of PsA in patients who were naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD-naïve) or patients who have previous inadequate response or intolerance to tumor necrosis factor (TNF) inhibitors (TNFi-IR)

What was learned from this study?

In patients who were bDMARD-naïve, bimekizumab had a greater likelihood of achieving at least a 70% improvement according to American College of Rheumatology response criteria (ACR70) outcome compared to secukinumab 150 mg and secukinumab 300 mg at 52 weeks

In patients who were TNFi-IR, bimekizumab had a greater likelihood of response compared to secukinumab 150 mg for ACR20, ACR70, and minimal disease activity (MDA) outcomes and a greater likelihood of response compared to secukinumab 300 mg for ACR50 and MDA outcomes at 52 weeks

Bimekizumab can be considered as more effective than, or at least comparable to, secukinumab in achieving long-term, positive treatment outcomes in PsA